Box 1.

Informed consent options and main objectives of PLCRC.

IC options within the PLCRC cohort
Mandatory
1. Informed consent for longitudinal observational clinical data collection
Optional
2. Informed consent for providing PRO (hard-copy or electronic)  (a) In case of electronic patient-reported outcomes (ePRO), patients can choose to receive a summarized evaluation of their HRQoL (incl. optional comparisons with average scores of sex- and age-matched CRC patients and/or the non-cancer population) and share these data with their healthcare professional
3. Informed consent to approach the patient for future studies and to use their data in comparative research according to the Trials within Cohorts (TwiCs) design
4. Informed consent for biobanking of (tumor) tissue
5. Informed consent for providing additional blood samples during routine blood withdrawal for observational studies or biobanking
6. Informed consent to receive information in case of new relevant DNA abnormalities
Objectives of the PLCRC cohort
To prospectively collect detailed data on medical history, serious comorbidities, basic physical examination, imaging results, pathology results, tumor characteristics, treatments, treatment outcomes, hospital stays, interventions and adverse events
To collect blood and (tumor) tissue material, obtained during routine practice, for ongoing and future research
To provide more accurate treatment data, and clinical and patient-reported outcomes of CRC in daily clinical practice
To create a continuous basis for a large variety of research purposes including, but not limited to:  Etiologic, diagnostic, and prognostic research  Basic and (epi)genetic research  Interventional studies according to TwiCs designs  Healthcare policy and cost-effectiveness studies